Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study

	Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
	Wu, Y. -L.2; Zhou, Q.3; Chen, M.4; Pan, Y.2; Jian, O.5; Hu, D.1; Lin, Q.6; Wu, G.7; Cui, J.8; Chang, J.9
刊名	JOURNAL OF THORACIC ONCOLOGY
	2022-09-01
卷号	17
关键词	CCRT sCRT PD-L1 inhibitor
ISSN号	1556-0864
WOS研究方向	Oncology ; Respiratory System
语种	英语
出版者	ELSEVIER SCIENCE INC
WOS记录号	WOS:000858678100012
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129843]
专题	中国科学院合肥物质科学研究院
作者单位	1.Hubei Canc Hosp, Wuhan, Peoples R China 2.Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China 3.Guangdong Lung Canc Inst, Guangzhou, Peoples R China 4.Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China 5.Second Peoples Hosp Neijiang, Neijiang, Peoples R China 6.Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China 7.Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China 8.Jilin Univ, Hosp 1, Jilin, Peoples R China 9.Fudan Univ, Canc Ctr, Shanghai, Peoples R China 10.Shandong Univ, Qilu Hosp, Jinan, Peoples R China
推荐引用方式 GB/T 7714	Wu, Y. -L.,Zhou, Q.,Chen, M.,et al. Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study[J]. JOURNAL OF THORACIC ONCOLOGY,2022,17.
APA	Wu, Y. -L..,Zhou, Q..,Chen, M..,Pan, Y..,Jian, O..,...&Yang, J..(2022).Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study.JOURNAL OF THORACIC ONCOLOGY,17.
MLA	Wu, Y. -L.,et al."Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study".JOURNAL OF THORACIC ONCOLOGY 17(2022).